SI3463351T1 - Zdravljenje parkinsove bolezni - Google Patents

Zdravljenje parkinsove bolezni

Info

Publication number
SI3463351T1
SI3463351T1 SI201731157T SI201731157T SI3463351T1 SI 3463351 T1 SI3463351 T1 SI 3463351T1 SI 201731157 T SI201731157 T SI 201731157T SI 201731157 T SI201731157 T SI 201731157T SI 3463351 T1 SI3463351 T1 SI 3463351T1
Authority
SI
Slovenia
Prior art keywords
parkinson
disease
treatment
Prior art date
Application number
SI201731157T
Other languages
English (en)
Slovenian (sl)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of SI3463351T1 publication Critical patent/SI3463351T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201731157T 2016-06-02 2017-06-02 Zdravljenje parkinsove bolezni SI3463351T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
SI3463351T1 true SI3463351T1 (sl) 2022-07-29

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731157T SI3463351T1 (sl) 2016-06-02 2017-06-02 Zdravljenje parkinsove bolezni

Country Status (26)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
EP3982964A1 (en) * 2019-06-11 2022-04-20 Sun Pharma Advanced Research Company Ltd Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665709B1 (en) * 2011-01-21 2016-12-07 Sun Pharma Advanced Research Company Limited Diarylacetylene hydrazide containing tyrosine kinase inhibitors
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
CA2985161A1 (en) * 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas

Also Published As

Publication number Publication date
PH12018502457B1 (en) 2022-01-12
US20190275017A1 (en) 2019-09-12
KR102508288B1 (ko) 2023-03-09
MY193754A (en) 2022-10-27
US20210015805A1 (en) 2021-01-21
LT3463351T (lt) 2022-06-10
EP3463351B1 (en) 2022-04-27
US20220273632A1 (en) 2022-09-01
SG11201810294QA (en) 2018-12-28
CL2018003431A1 (es) 2019-05-10
UA123018C2 (uk) 2021-02-03
US11813252B2 (en) 2023-11-14
PL3463351T3 (pl) 2022-06-20
DK3463351T3 (da) 2022-06-07
HRP20220683T1 (hr) 2022-07-08
IL263188B (en) 2021-08-31
RS63243B1 (sr) 2022-06-30
CA3024976A1 (en) 2017-12-07
CN109475539A (zh) 2019-03-15
SMT202200228T1 (it) 2022-07-21
US20240066014A1 (en) 2024-02-29
IL263188A (en) 2018-12-31
MX2018014944A (es) 2019-03-07
MX385276B (es) 2025-03-18
CN109475539B (zh) 2021-12-28
KR20190015257A (ko) 2019-02-13
US10849887B2 (en) 2020-12-01
AU2017273415A1 (en) 2018-12-06
CY1125285T1 (el) 2025-03-28
BR112018074439A2 (pt) 2019-03-06
PH12018502457A1 (en) 2019-10-21
JP6974357B2 (ja) 2021-12-01
HUE059387T2 (hu) 2022-11-28
US11583522B2 (en) 2023-02-21
ES2914782T3 (es) 2022-06-16
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
NZ748592A (en) 2025-11-28
EP3463351A1 (en) 2019-04-10
PT3463351T (pt) 2022-06-02
WO2017208267A1 (en) 2017-12-07
EP4085912A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
IL252433B (en) Methods for treating Alzheimer's disease
IL247085A0 (en) Methods for treating Alzheimer's disease
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
IL263188B (en) Treatment for Parkinson's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
ZA201605341B (en) Methods of treating alzheimer's disease
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
EP3244897A4 (en) Methods for treating alzheimer's disease
EP3244898A4 (en) Methods for treating psychosis associated with parkinson's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK40014282A (en) Methods for treating parkinson's disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201414038D0 (en) Alzheimer's disease